US · IONS
Ionis Pharmaceuticals, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Carlsbad, CA 92010
- Website
- ionispharma.com
Price · as of 2025-12-31
$75.28
Market cap 13.14B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $48.64 | -35.39% |
| Intrinsic Value(DCF) | $32.78 | -56.46% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $8.31 | $24.07 | $0.71 | $0.00 | $0.08 |
| 2012 | $17.70 | $33.67 | $0.73 | $0.00 | $0.00 |
| 2013 | $51.22 | $92.12 | $2.59 | $0.68 | $0.00 |
| 2014 | $70.66 | $58.27 | $54.98 | $0.53 | $0.00 |
| 2015 | $39.07 | $38.23 | $123.44 | $0.00 | $0.00 |
| 2016 | $41.84 | $95.72 | $98.51 | $0.00 | $0.00 |
| 2017 | $52.98 | $67.87 | $191.34 | $2.28 | $0.12 |
| 2018 | $70.46 | $70.15 | $119.77 | $18.27 | $49.67 |
| 2019 | $53.88 | $83.17 | $2,721.26 | $20.44 | $181.87 |
| 2020 | $52.99 | $47.80 | $203.93 | $0.00 | $80.66 |
| 2021 | $32.19 | $43.40 | $58.74 | $4.46 | $0.00 |
| 2022 | $33.96 | $106.42 | $0.00 | $0.00 | $34.74 |
| 2023 | $43.99 | $36.75 | $0.00 | $0.00 | $0.00 |
| 2024 | $33.81 | $30.31 | $0.00 | $0.00 | $5.52 |
| 2025 | $81.96 | $48.64 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Ionis Pharmaceuticals, Inc.'s (IONS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $48.64
- Current price
- $75.28
- AI upside
- -35.39%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$32.78
-56.46% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IONS | Ionis Pharmaceuticals, In… | $75.28 | 13.14B | -35% | -56% | — | — | -34.38 | 26.82 | 13.89 | -46.25 | — | 26.82 | 98.31% | -40.47% | -40.36% | -70.80% | -221.28% | -11.69% | 5.78 | -5.23 | 1.95 | 1.79 | -8.56 | -2171.00% | 3387.00% | -4141.00% | -2.44% | -0.18 | -185.38% | 0.00% | 0.00% | 0.00% | -34.72 | -41.44 | 14.05 | 1.95 |
| ASND | Ascendis Pharma A/S | $233.50 | 14.33B | -41% | +2,942% | — | — | -57.24 | -77.03 | 18.12 | -112.32 | — | -75.32 | 85.08% | -18.92% | -31.67% | 163.18% | -92.10% | -17.65% | -5.35 | -1.69 | 1.04 | 0.72 | -2.24 | -4456.00% | 9022.00% | -11418.00% | 0.35% | 0.05 | 30.69% | 0.00% | 0.00% | 0.46% | -97.73 | 293.28 | 18.49 | 2.47 |
| BBIO | BridgeBio Pharma, Inc. | $66.48 | 12.89B | -12% | +7,582% | — | — | -17.82 | -6.22 | 25.73 | -22.38 | -56.40 | -6.14 | 94.37% | -113.35% | -145.26% | 40.90% | 321.74% | -78.14% | -1.31 | -10.72 | 2.62 | 2.52 | -3.21 | 3160.00% | 12626.00% | -1431.00% | -3.46% | -1.55 | 252.72% | 0.00% | 0.00% | 0.37% | -26.46 | -33.69 | 30.00 | -4.02 |
| BMRN | BioMarin Pharmaceutical I… | $61.73 | 11.86B | +37% | -52% | -36% | -40% | 32.84 | 1.88 | 3.56 | 18.32 | — | 2.02 | 77.13% | 16.56% | 10.83% | 5.94% | 7.50% | 4.79% | 0.10 | 48.95 | 5.21 | 3.25 | -1.25 | -1855.00% | 1287.00% | 5249.00% | 6.33% | 1.09 | 14.09% | 0.00% | 0.00% | 3.68% | 19.67 | 14.48 | 3.26 | 5.75 |
| EXEL | Exelixis, Inc. | $44.06 | 11.81B | +59% | -51% | -50% | -3% | 14.24 | 5.16 | 4.80 | 11.13 | 24.57 | 5.31 | 96.39% | 37.59% | 33.73% | 35.53% | 55.80% | 27.02% | 0.08 | — | 3.56 | 3.32 | -0.34 | 5795.00% | 698.00% | 3322.00% | 7.58% | 2.18 | 64.97% | 0.00% | 0.00% | 11.04% | 11.76 | 12.15 | 4.42 | 12.01 |
| GH | Guardant Health, Inc. | $93.90 | 12.32B | -39% | -48% | — | — | -27.78 | -116.44 | 11.77 | -32.21 | — | -57.11 | 64.46% | -44.43% | -42.39% | 348.42% | -117.88% | -23.79% | -16.94 | -111.96 | 4.84 | 4.42 | -3.49 | -674.00% | 3288.00% | -1523.00% | -2.02% | -0.61 | -63.16% | 0.00% | 0.00% | 0.12% | -27.61 | -51.68 | 12.26 | 1.67 |
| MDGL | Madrigal Pharmaceuticals,… | $432.00 | 9.81B | -42% | +134,896% | — | — | -33.90 | 16.22 | 10.20 | -34.57 | — | 16.42 | 94.14% | -31.31% | -30.08% | -42.49% | 761.60% | -25.05% | 0.59 | -13.45 | 4.01 | 3.60 | -0.59 | -4132.00% | 43205.00% | -5842.00% | -1.94% | -0.61 | 482.24% | 0.00% | 0.00% | 0.00% | -30.47 | -48.12 | 9.54 | 7.47 |
| MRNA | Moderna, Inc. | $53.57 | 20.93B | -39% | -52% | — | +298% | -7.28 | 2.38 | 10.57 | -6.53 | — | 2.38 | 55.35% | -158.13% | -145.16% | -28.87% | -65.47% | -21.31% | 0.22 | — | 3.29 | 3.01 | 0.27 | -2168.00% | -3923.00% | -4908.00% | -10.05% | -0.94 | -43.98% | 0.00% | 0.00% | 0.00% | -5.42 | -8.07 | 8.58 | 3.94 |
| ROIV | Roivant Sciences Ltd. | $28.94 | 20.71B | +3% | -75% | -82% | -98% | -22.84 | 1.74 | 280.39 | -3.06 | — | 1.74 | 96.86% | -3453.32% | -591.96% | -6.70% | 1167.58% | -5.64% | 0.02 | — | 33.47 | 32.71 | 2.38 | -10459.00% | -1119.00% | 1010.00% | -10.36% | -5.62 | 982.26% | 0.00% | 0.00% | 15.88% | -3.35 | -3.98 | 115.63 | 20.07 |
| RVMD | Revolution Medicines, Inc… | $102.02 | 19.72B | — | — | — | — | -17.08 | 11.84 | — | -16.01 | -25.80 | 12.38 | 0.00% | — | — | -58.07% | 1908.09% | -46.06% | 0.10 | -48.80 | 7.14 | 6.97 | 0.21 | 6620.00% | — | 6094.00% | -4.73% | -3.09 | 1474.57% | 0.00% | 0.00% | 0.00% | -14.76 | -19.10 | — | 13.58 |
| SMMT | Summit Therapeutics Inc. | $16.59 | 12.35B | — | — | — | — | -11.21 | 18.37 | — | -14.24 | -3.08 | 18.43 | 0.00% | — | — | -206.10% | 2928.71% | -181.94% | 0.02 | — | 9.87 | 9.77 | 0.26 | 36452.00% | — | 12749.00% | -2.67% | -4.42 | 1166.77% | 0.00% | 0.00% | 0.93% | -14.04 | -35.25 | — | 72.96 |
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
- CEO
- Brett Monia
- Employees
- 1.07K
- Beta
- 0.31
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($32.78 ÷ $75.28) − 1 = -56.46% (DCF, example).